Spyre Therapeutics, Inc. (SYRE) एक सार्वजनिक रूप से कारोबार करने वाली कंपनी है में स्वास्थ्य सेवा क्षेत्र, संचालन करती है Biotechnology उद्योग. कंपनी का मुख्यालय है Waltham, MA, United States. वर्तमान CEO हैं Cameron Turtle.
SYRE के पास है IPO तिथि 2016-04-07, 73 पूर्णकालिक कर्मचारी, पर सूचीबद्ध NASDAQ Capital Marke, बाजार पूंजीकरण $4.17B.
Spyre Therapeutics, Inc. is a preclinical-stage biotechnology company focused on developing innovative therapies for inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease. The company's lead candidate, SPY001, is a human monoclonal antibody targeting the α4β7 integrin, designed to selectively treat IBD patients. Spyre's pipeline also includes SPY002, which targets tumor necrosis factor-like ligand 1A, along with several combination and early-stage programs such as SPY003 (anti-IL-23), SPY004, and various combination therapies currently in preclinical development. Incorporated in 2013 and headquartered in Waltham, Massachusetts, the company was formerly known as Aeglea BioTherapeutics before rebranding to Spyre Therapeutics in November 2023.
